Additional drug approvals and launches are on the way.
News & Analysis: Alnylam Pharmaceuticals
Investors are starting to wonder if there's anything that can lift this stock higher.
ALNY earnings call for the period ending March 31, 2019.
Everything's falling into place for the pioneer of RNA interference.
Here's what you need to know about two biotechs that will present trial results that could send their stock prices soaring -- or plummeting.
The biotech has launched its first drug, Onpattro, but don't forget about its pipeline of drugs to come.
ALNY earnings call for the period ending December 31, 2018.
The biotech gave investors reasons to cheer at the J.P. Morgan Healthcare Conference
A first-in-kind FDA approval catapulted this treatment approach into the spotlight.
Unfortunately, predicting the steepness of the launch is going to be tough.